Table 3.
| NRTI | Primary Mutations |
|---|---|
| Zidovudine (ZDV) | K70R, T215T/F, M41L, D76N, M184V, T215Y, K219N, T215F |
| Lamivudine (3TC) | M184V/I, E44D, V1181, M41L, D76N, M184V, T215Y, K219N, T215F, K70R, K219Q, L210W, A62V, L74V |
| Didanosine (ddl) | L74V, A62V, D67N, K70R, V75L, F116Y, Q151M, K219Q, M41L, M184V, L210W, T215Y, T215F |
| MDR1 | Q151M |
| MDR2 | T69S, thymidine analog mutations |
| Abacavir (ABC) | K65R, L74V, Y115F, M184V/I, M41L, D67N, T215Y, K219N/Q, A62V, K70R, V75I, F116Y, Q151M, L210W |
| Tenofovir (TFV) | K65R, M41L, L210W |
| Stavudine (d4T) | M41L, M184V, T215Y, A62V, D67N, K70R, V75I, F116Y, Q151M. K219Q |
NRTI, nucleoside reverse transcriptase inhibitors; MDR, multiple drug resistance.